Lee, Chang-Hoon
Kim, Mi-Sook
Yeo, See-Hwee
Rhee, Chin-Kook
Park, Heung-Woo
Yang, Bo-Ram
Lee, Joongyub
Cho, Eun-Yeong
Xu, Xiaomeng
Navarro Rojas, Aldo Amador
Shantakumar, Sumitra
Milea, Dominique
Choi, Nam-Kyong http://orcid.org/0000-0003-1153-9928
Funding for this research was provided by:
GlaxoSmithKline (208052, 208052, 208052, 208052, 208052, 208052, 208052)
Article History
Received: 7 April 2022
Accepted: 10 June 2022
First Online: 5 September 2022
Declarations
:
: This study complied with all applicable laws regarding patient privacy. No direct patient contact or primary collection of individual human subject data occurred. Study results were in tabular form and presented as aggregate analyses that omit patient identification, therefore informed consent, ethics committee or Institutional Review Board (IRB) review was not required as deemed by EWHA IRB.
: Not applicable.
: CHL: Received research funding from GSK. MSK: Received research funding from GSK. SHY: Employee of GSK at the time the study was conducted. CKR: Received consulting/lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, GSK, MSD, Mundipharma, Novartis, Sanofi, Takeda and Teva Pharmaceuticals. HWP: Received research funding from GSK. BRY: Received research funding from GSK. JL: Received research funding from GSK. EYC: Employee of GSK. XX: Employee of GSK. AN: Employee of, and shareholder in, GSK. SS: Employee of GSK. DM: Employee of, and shareholder in, GSK. NKC: Received research funding from GSK.